Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2009 Jul 21;101(2):238-43.
doi: 10.1038/sj.bjc.6605167. Epub 2009 Jun 30.

Sunitinib and bevacizumab for first-line treatment of metastatic renal cell carcinoma: a systematic review and indirect comparison of clinical effectiveness

J S Thompson Coon  1 , Z Liu, M Hoyle, G Rogers, C Green, T Moxham, K Welch, K Stein
Affiliations
Comparative Study

Sunitinib and bevacizumab for first-line treatment of metastatic renal cell carcinoma: a systematic review and indirect comparison of clinical effectiveness

J S Thompson Coon et al. Br J Cancer. .

Abstract

Background: Two new agents have recently been licensed for use in the treatment of metastatic renal cell carcinoma (RCC) in Europe. This paper aims to systematically review the evidence from all available randomised clinical trials of sunitinib and bevacizumab (in combination with interferon-alpha (IFN-alpha)) in the treatment of advanced metastatic RCC.

Methods: Systematic literature searches were performed in six electronic databases. Bibliographies of included studies were searched for further relevant studies. Individual conference proceedings were searched using their online interfaces. Studies were selected according to the predefined criteria. All randomised clinical trials of sunitinib or bevacizumab in combination with IFN for treating advanced metastatic RCC in accordance with the European licensed indication were included. Study selection, data extraction, validation and quality assessment were performed by two reviewers with disagreements being settled by discussion. The effects of sunitinib and bevacizumab (in combination with IFN-alpha) on progression-free survival were compared indirectly using Bayesian Markov Chain Monte-Carlo (MCMC) sampling in Win BUGS, with IFN as a common comparator.

Results: Three studies were included. Median progression-free survival was significantly prolonged with both interventions (from approximately 5 months to between 8 and 11 months) compared with IFN. Overall survival was also prolonged, compared with IFN, although the published data are not fully mature. Indirect comparison suggests that sunitinib is superior to bevacizumab plus IFN in terms of progression-free survival (hazard ratios 0.796; 95% CI 0.63-1.0; P=0.0272).

Conclusion: There is evidence to suggest that treatment with sunitinib and treatment with bevacizumab plus IFN has clinically relevant and statistically significant advantages over treatment with IFN alone in patients with metastatic RCC.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Flow chart of trial selection process.
See this image and copyright information in PMC

Comment in

References

    1. Ades AE (2003) A chain of evidence with mixed comparisons: models for multi-parameter synthesis and consistency of evidence. Stat Med 22: 2995–3016 - PubMed
    1. Bajetta E, Ravaud A, Bracarda S, Negrier S, Szczylik C, Bellmunt J, Moore N, Pisa P, Escudier BJ (2008) Efficacy and safety of first-line bevacizumab (BEV) plus interferon-a2a (IFN) in patients (pts)>65 years with metastatic renal cell carcinoma (mRCC). J Clin Oncol 26: 5095
    1. Bracarda S, Koralewski R, Pluzanska A, Ravaud A, Szczylik C, Chevreau C, Filipek M, Melichar B, Moore N, Escudierlo B (2007) Bevacizumab/interferon-alpha2a provides a progression-free survival benefit in all prespecified patient subgroups as first-line treatment of metastatic renal cell carcinoma (AVOREN). Ejc Supplements 5: 281–282
    1. Coppin C, Porzsolt F, Awa A, Kumpf J, Coldman A, Wilt T (2005) Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev (1): CD001425 - PubMed
    1. Escudier B, Koralewski P, Pluzanska A, Ravaud A, Bracarda S, Szczylik C, Chevreau C, Filipek M, Melichar B, Moore N, on behalf of the AVOREN investigators (2007) A randomised, controlled, double blind phase III study (AVOREN) of bevacizumab/interferon-a2a vs placebo/interferon a2a as first line therapy in metastatic renal cell carcinoma. J Clin Oncol 25: 3. - PubMed

MeSH terms